CA3015331C - Derive 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one - Google Patents

Derive 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one

Info

Publication number
CA3015331C
CA3015331C CA3015331A CA3015331A CA3015331C CA 3015331 C CA3015331 C CA 3015331C CA 3015331 A CA3015331 A CA 3015331A CA 3015331 A CA3015331 A CA 3015331A CA 3015331 C CA3015331 C CA 3015331C
Authority
CA
Canada
Prior art keywords
methyl
dihydro
pyridazin
chloro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3015331A
Other languages
English (en)
Other versions
CA3015331A1 (fr
Inventor
Takahiro Katoh
Masatoshi Iida
Yuki Terauchi
Kazuya Yamaguchi
Toshiyuki Hirose
Fumiharu YOKOYAMA
Hikaru Nishimori
Yutaka Obuchi
Hiroshi NABESHIMA
Emiri TAKAKI
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority claimed from PCT/JP2017/008246 external-priority patent/WO2017150654A1/fr
Publication of CA3015331A1 publication Critical patent/CA3015331A1/fr
Application granted granted Critical
Publication of CA3015331C publication Critical patent/CA3015331C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne un agent pour le traitement de tumeurs malignes, comprenant un composé de formule (1) dans laquelle R1 to R4 représentent un atome d'hydrogène, halogène, ou analogue; Y représente un groupe alkylène éventuellement substitué ou analogue.
CA3015331A 2016-03-04 2017-03-02 Derive 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one Active CA3015331C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016042535 2016-03-04
JP2016-042535 2016-03-04
PCT/JP2017/008246 WO2017150654A1 (fr) 2016-03-04 2017-03-02 Dérivé 5-méthyl-6-phényl -4,5-dihydro -2 h-pyridazin-3-one

Publications (2)

Publication Number Publication Date
CA3015331A1 CA3015331A1 (fr) 2017-09-08
CA3015331C true CA3015331C (fr) 2025-09-23

Family

ID=

Similar Documents

Publication Publication Date Title
RU2655914C2 (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
US20240400520A1 (en) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative
WO2018008711A1 (fr) Combinaison comprenant un antagoniste de l'ep4 et un inhibiteur de point de contrôle immunitaire
JPWO2011132712A1 (ja) 新規なヒドロキサム酸誘導体
KR20230145111A (ko) 히드록시헤테로시클로알칸-카르바모일 유도체
KR20230104190A (ko) 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
CN104220437A (zh) 新α2肾上腺素受体激动剂
JPWO2020027150A1 (ja) ベンゼン誘導体
IL323168A (en) Tricyclic compound
CA3015331C (fr) Derive 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one
JP7104588B2 (ja) ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤
BR112018017324B1 (pt) Derivado de 5-metil-6-fenil-4,5-di-hidro-2h-piridazin-3-ona
WO2024190780A1 (fr) Agent prophylactique et/ou thérapeutique pour maladies rénales contenant un composé tricyclique
HK1259592B (en) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative for the treatment of brain tumors
HK1259592A1 (en) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative for the treatment of brain tumors
KR20250152592A (ko) Gba1 및 gcs 이중 조절제